Article

Identification of a novel member of mouse hsp70 family. Its association with cellular mortal phenotype.

Aging Process Research Laboratory, Tsukuba Life Science Center, Ibaraki, Japan.
Journal of Biological Chemistry (Impact Factor: 4.6). 04/1993; 268(9):6615-21.
Source: PubMed

ABSTRACT A novel 66-kDa protein, named p66mot-1, is identified to be associated with cellular mortality by virtue of its presence in cytosolic fractions of serially passaged mouse embryonic fibroblasts (MEF) and the mortal hybrids obtained by the fusion of mortal (MEF) and immortal (MN48-1, derivative of NIH 3T3) cells. Immortal cells lack this protein in their cytosolic fractions. cDNA cloning and homology search placed it in the heat shock protein 70 (hsp70) family. Microinjection of anti-p66 antibody to senescent MEF could transiently stimulate their cell division, which supports the cellular mortality-related function of p66mot-1.

0 Followers
 · 
75 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Heat shock proteins (HSP) perform vital cellular functions and modulate cell response pathways to physical and chemical stressors. A key feature of HSP function is the ability to interact with a broad array of protein binding partners as a means to potentiate downstream response pathways or facilitate protein folding. These binding interactions are driven by ATP-dependent conformational rearrangements in HSP proteins. The HSP70 family is evolutionarily conserved and is associated with diabetes and cancer progression and the etiopathogenesis of hepatic, cardiovascular, and neurological disorders in humans. However, functional characterization of human HSP70s has been stymied by difficulties in obtaining large quantities of purified protein. Studies of purified human HSP70 proteins are essential for downstream investigations of protein–protein interactions and in the rational design of novel family-specific therapeutics. Within this work, we present optimized protocols for the heterologous overexpression and purification of either the nucleotide binding domain (NBD) or the nucleotide and substrate binding domains of human HSPA9, HSPA8, and HSPA5in either Escherichiacoli or Saccharomycescerevisiae. We also include initial biophysical characterization of HSPA9 and HSPA8.This work provides the basis for future biochemical studies of human HSP70 protein function and structure.
    Protein Expression and Purification 09/2014; 106. DOI:10.1016/j.pep.2014.09.013 · 1.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this chapter we demonstrate the remarkable sequence homology be-tween mortalin proteins from a broad array of invertebrate taxa, including the few species for which functional analyses have been conducted. We also discuss expres-sion and functional data for full-length and truncated clam homologs for human mortalin and their function in cytoplasmic sequestration in cancerous clam hemo-cytes. Both clam proteins have N-terminal mitochondrial targeting and p53 binding domains, though the truncated variant is missing exon 3 containing the N-terminal ATP/ADP binding and ATPase domains. Both variants are over-expressed and com-plexed with p53 and both may be responsible for cytoplasmic sequestration of p53 in cancerous clam hemocytes. Clam hemocyte cancer is the only animal model thus far investigated where cytoplasmically sequestered wild-type p53 can be reactivated both in vitro and in vivo using both genotoxic and non-genotoxic therapies. Our results suggest that mortalin-based cytoplasmic sequestration of wild-type p53 in cancerous clam hemocytes can be reversed by treatment with antineoplastic drugs also employed against similar human diseases and will result either in transcription-based apoptosis when the nucleus is accessible or non-transcription-based apoptosis when nuclear access is blocked., © Springer Science+Business Media B.V. 2012
    01/2012;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mortalin binds to p53 tumor suppressor protein and sequesters it in the cytoplasm. This results in an inhibition of the transcriptional activation and control of centrosome duplication functions of p53, thus contributing to human carcinogenesis. Abrogation of mortalin-p53 interaction and reactivation of p53 function could be a valid proposition for cancer therapy. In the present study, we first investigated in silico the interaction of withanone, a withanolide with anticancer activity, with mortalin. We found that withanone could bind to mortalin in a region, earlier predicted critical for binding to p53. Cationic rhodacyanine dye, MKT-077 has also shown to bind the same region and kill cancer cells selectively. We report the molecular dynamic simulations revealing the thermodynamic and structural stability of the withanone-mortalin complexes. We also demonstrate the experimental evidence of abrogation of mortalin-p53 complex by withanone resulting in nuclear translocation and functional reactivation of p53 in human cancer cells. The present study establishes a molecular interaction basis that could be used for screening and development of anticancer drugs with low toxicity to normal cells. Accurate knowledge of the 3D structure of mortalin would further enhance the potential of such analyses to understand the molecular basis of mortalin biology and mortalin based cancer therapy.
    The international journal of biochemistry & cell biology 12/2011; 44(3):496-504. DOI:10.1016/j.biocel.2011.11.021 · 4.24 Impact Factor

Preview

Download
0 Downloads
Available from